Milan, le 29 octobre 2008 - Recordati annonce la signature d'un accord pour l'acquisition de Yeni Ilaç, société pharmaceutique turque dont le siège est situé près d'Istanbul. Le montant s'élève à 48 millions d'euros et sera financé par les liquidités existantes. La finalisation de la transaction, prévue avant la fin de l'année 2008, est soumise à certaines conditions, dont l'accord des autorités compétentes.
Fondée en 1927, Yeni Ilaç est une société pharmaceutique turque renommée, spécialisée dans la production, le marketing et la vente de médicaments propriétaires et sous licences. Ses produits sont très connus, en particulier pour les pathologies urologiques, marché où la société est leader. The company is also engaged in contract manufacturing for other pharmaceutical companies. Yeni Ilaç employs 300 personnel, of which around 100 are medical representatives. The company is very solid financially and has a positive net financial position. Sales have increased consistently over recent years and in 2008 are expected to be around E 17 million. Operating profit margins are positive and in line with group margins.
The Turkish pharmaceutical market is thirteenth worldwide and is in continuous expansion, with a growth rate of over 15% in recent years, due to its population growth and increasing average age within a national economic context which shows growing GDP and where healthcare expenditure is still relatively low.
Recordati has been present in Turkey for some time through licensing agreements with local companies which have allowed it to assert its original products in this market, in particular lercanidipine. Sales of these products are currently of around E 7 million and have important market shares in their respective classes. In particular, combination products are well accepted for the treatment of hypertension in the cardiovascular area of the Turkish market. This is a strategic area for Recordati which will be launching in 2009, on a worldwide basis, its own product combining lercanidipine with enalapril.
"The acquisition of Yeni Ilaç allows us to be present directly in a market with high growth rates, where, in addition, our products have already been present successfully for some time" declared Giovanni Recordati, Chairman and CEO. "We will therefore be able to realize significant synergies in this market from the start. We also intend to double the current field force of our new subsidiary in order to both increase the sales of the existing portfolio and to adequately prepare ourselves for the launch of the new products in our pipeline, in particular in the cardiovascular area (lercanidipine+enalapril combination, pitavastatin) and in the area of urology (Kentera®, silodosin). The acquisition of Yeni Ilaç represents a further step ahead in our strategy, which we confirm and intend to strengthen, to develop a direct presence of our group in the emerging markets of Central and Eastern Europe."
Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, isin IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,400. A European field force of over 1,300 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research TEAM has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2007 was E 628.4 million, operating income was E 131.5 million and net income was E 84.9 million.
For further information:
Recordati website: www.recordati.com
Claudio Rossetti (Echo Comunicazione d'Impresa)
Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.